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ABSTRACT 23 
In drug development, the stomach is often considered to be a simple, one-compartmental organ, a 24 
waiting room for transfer of an orally administered dosage form to the duodenum. However, factors 25 
such as gastric acidity and hydrodynamics in the gastric environment may influence drug disposition. 26 
Although a link between gastrointestinal drug behaviour and gastric motility has often been 27 
hypothesized, they have not been simultaneously investigated in humans yet. In this proof-of-concept 28 
study, the combination of a well-established intraluminal sampling technique with high-resolution 29 
manometric measurements in the gastrointestinal tract was evaluated. This new combination of in vivo 30 
techniques proved to be feasible from a practical point of view and yielded valuable additional 31 
information regarding intraluminal drug behaviour. As a first application, the link between fasted state 32 
gastric motility and (in)homogeneous distribution of an orally administered drug in the stomach was 33 
investigated in healthy subjects. To this end, drug concentrations were measured in different regions of 34 
the stomach after oral administration of a commercially available drug product (Gabbroral®, 250 mg 35 
paromomycin) during a specific period of gastric contractile activity. A clear trend towards better 36 
mixing of an orally administered drug with gastric contents was observed when dosed in the presence 37 
of gastric contractions, resulting in a more homogeneous distribution of the drug throughout the 38 
stomach compared to dosing in the absence of gastric contractions.  39 
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1. INTRODUCTION 51 
After oral administration, most drugs travel along the gastrointestinal tract to eventually be absorbed at 52 
the level of the small and/or large intestine. Before reaching these sites of absorption, a drug first has 53 
to migrate through several other sites (e.g. oral cavity, oesophagus and stomach). As passage through 54 
the mouth and oesophagus occurs rapidly, the stomach is typically the first compartment in which a 55 
drug resides for a longer period of time [1-3].  56 
Although several anatomical regions in the stomach have since long been identified [4, 5], these are 57 
seldom recognized in drug development. When evaluating drugs and formulations, the stomach is 58 
often considered to be a simple, one-compartmental organ in which a drug awaits transfer to the 59 
duodenum relatively undisturbed. This is illustrated by the fact that most in vitro dissolution tools use 60 
a single vessel to mimic the gastric environment and only account for the acidity of the stomach, 61 
hereby neglecting other gastric physiological factors that potentially affect drug disposition. For 62 
instance, hydrodynamics are often introduced in these systems by means of stirring bars, creating fluid 63 
flow patterns which are not at all representative for the in vivo situation [6, 7]. By oversimplifying the 64 
dynamic gastric environment regarding motility, processes such as dosage form disintegration, drug - 65 
gastric fluid mixing and gastric emptying may be incorrectly simulated in in vitro systems.  66 
Gastric motor function is characterized by predominant tonic contractions in the proximal region and 67 
peristaltic contractions in the distal region of the stomach [8]. Peristaltic contractions originate in the 68 
midcorpus region and migrate towards the pylorus, meanwhile increasing in both amplitude and 69 
velocity [9]. During the interdigestive state, periods of contractile quiescence alternate periods of 70 
contractile activity in a continuous cycle called the ‘Migrating Motor Complex (MMC)’ [10, 11]. 71 
Generally, this cyclical pattern consists of three phases. The absence of contractions is characteristic 72 
for MMC phase I. Moderate peristaltic contractions (mean: 39.7 ± 14.4 mmHg; n = 40) with irregular 73 
frequency mark the beginning of MMC phase II activity. As phase II transitions into phase III activity, 74 
the amplitude of these contractions further increases (mean: 88 ± 31.7 mmHg) [12]. MMC phase III 75 
can either originate in the stomach or the small intestine. In the stomach, this phase is generally of 76 
short duration (2 - 6 min) and is characterized by a regular contraction frequency (2 - 3 77 
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contractions.min-1) [11, 12]. Although marked variation within and between subjects has been 78 
observed, mean duration of one MMC cycle is often reported to range between 1.5 and 2 hours [12-79 
16]. 80 
As the presence, amplitude and frequency of gastric contractions under fasted state conditions 81 
fluctuates in a time-dependent manner, an orally administered drug may exhibit variable behaviour 82 
(e.g. disintegration, distribution) depending on the time of administration relative to the MMC phase. 83 
Although gastrointestinal motility itself has been the subject of extensive research efforts, both in 84 
animal species and humans, the direct link between motility and drug disposition can still be 85 
considered mainly uncharted territory [9, 10, 17-19]. In recent years, wireless motility capsule studies 86 
have yielded important information regarding biorelevant pressures exerted on non-disintegrating 87 
dosage forms and their relation to gastric emptying [20-22]. Furthermore, some work has been 88 
performed to visualize tablet erosion in the stomach due to mixing of the dosage form with gastric 89 
contents [23].  Efforts have been made to translate the in vivo obtained data to in vitro predictive tools 90 
to be used during drug development, in order to better reflect in vivo gastric motility (e.g. dynamic 91 
gastric model, TIM-advanced gastric compartment) [24-27]. Nevertheless, a clear need still exists to 92 
better understand fundamental drug disposition processes such as dosage form disintegration and drug 93 
distribution in relation to gastric motor function. Although the link between drug behaviour and gastric 94 
motility has often been hypothesized, it has not been demonstrated in vivo so far. To this end, this 95 
study assessed the feasibility of combining intraluminal sampling of gastrointestinal fluids after oral 96 
drug administration, a well-established approach to elucidate gastrointestinal drug behaviour [28], 97 
with simultaneous motility measurements. As a first application of this new combination of in vivo 98 
techniques, the link between fasted state gastric motility and (in)homogeneous distribution of an orally 99 
administered drug in the stomach was investigated in healthy subjects.  100 
 101 
2. MATERIALS AND METHODS 102 
2.1. Chemicals 103 
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Paromomycin sulfate, glycine and 9-fluorenylmethoxy-carbonyl chloride (Fmoc-Cl) were purchased 104 
from Sigma-Aldrich (Diegem, Belgium). Boric acid was acquired via Acros Organics (99.5%, for 105 
analysis; Geel, Belgium). Chem-Lab (Zedelgem, Belgium) supplied acetic acid, while sodium acetate 106 
trihydrate (NaOAc.3H2O) was ordered from VWR (Leuven, Belgium). Acetonitrile and methanol 107 
were purchased from Fisher Scientific (HPLC grade; Leicestershire, UK) and Acros Organics (HPLC 108 
grade; Geel, Belgium), respectively. Purified water for analytical purposes was obtained using a 109 
Maxima system (Elga Ltd., High Wycombe Bucks, UK). 110 
 111 
2.2. Clinical trials 112 
2.2.1.  Clinical trial approval 113 
Clinical trials followed the tenets of the Declaration of Helsinki and were approved by the Federal 114 
Agency for Medicines and Health Products (FAMHP; EudraCT reference number 2013-000297-30) 115 
and the Medical Ethics Committee of the University Hospitals Leuven (ML9149).  116 
 117 
2.2.2. Clinical trial medication 118 
Clinical trial medication, i.e. Gabbroral® (250 mg paromomycin; Pfizer, New York City, NY, USA), 119 
was ordered via the hospital pharmacy of the University Hospitals of Leuven (UZ Leuven, Belgium). 120 
 121 
2.2.3. Preliminary clinical trial 122 
In a pilot study with healthy human volunteers, gastric fluids were collected from different regions of 123 
the stomach, i.e. corpus and antrum, as a function of time at predetermined time-points after oral 124 
administration of one tablet of Gabbroral® (250 mg paromomycin) with 240 mL of tap water. Gastric 125 
fluids were aspirated using the well-established intraluminal sampling technique [28]. This technique 126 
comprises the positioning of double-lumen catheters (Salem SumpTM PVC Gastroduodenal Tube, 14 127 
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Ch (4.7 mm) x 108 cm; Covidien, Dublin, Ireland) via nose and/or mouth in a region of interest in the 128 
gastrointestinal tract using fluoroscopic guidance. Subsequently, gastrointestinal contents can be 129 
aspirated as a function of time providing valuable information regarding intraluminal drug disposition 130 
[29-32]. 131 
 132 
2.2.4. Clinical trial investigating drug distribution 133 
Based on results obtained from the preliminary clinical trial, a cross-over trial was conducted 134 
including eight healthy volunteers (6 males, 2 females; age range: 20 - 26 years old). Candidate 135 
subjects were excluded from participation in case of (potential) pregnancy, frequent exposure to 136 
ionizing radiation in the previous year, history of gastrointestinal pathology and/or illness at the time 137 
of the study. Furthermore, Hepatitis B/C- or HIV-infected subjects were not allowed to participate in 138 
order to ensure the safety of the personnel conducting the study.  139 
Volunteers were asked to refrain from eating and only consume water 12 hours prior to the start of the 140 
study in order to ensure fasted state conditions. After providing written informed consent the day of 141 
the study, double-lumen catheters were positioned in the corpus and antrum region of the stomach, 142 
respectively (cfr. 2.2.3. Preliminary clinical trial). Additionally, a high-resolution manometry catheter 143 
(diameter 4.2 mm; Acertys, Aartselaar, Belgium) was introduced in the subject’s duodenum via 144 
passage through the nose and the stomach. This catheter consists of 36 pressure sensors spaced 1 cm 145 
apart, providing the possibility of measuring regional pressures in both stomach and duodenum. By 146 
connecting the outer end of the catheter to a computer console, specialized computer software 147 
(Manoview Analysis™, version 2.0.1, Los Angeles, CA, USA) generates a high-resolution pressure 148 
map, facilitating real-time monitoring of pressure events and enabling drug administration during a 149 
specific phase of gastric contractions. Based on the generated high-resolution pressure map, 150 
quantification of the contraction amplitude is theoretically possible. However, due to limitations in the 151 
instrumentation available and as this study aimed to qualitatively assess the link between gastric 152 
motility and intragastric drug distribution, quantification was not pursued. 153 
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 154 
Following conditions were tested on different days with a minimum wash-out period of two days:  155 
- Oral administration of one tablet of Gabbroral® (250 mg paromomycin) with 240 mL of tap 156 
water during MMC phase I (i.e. absence of contractions). 157 
- Oral administration of one tablet of Gabbroral® (250 mg paromomycin) with 240 mL of tap 158 
water during MMC phase II (i.e. period of gastric contractions).  159 
In both test conditions, gastric fluids were collected from both the corpus and antrum region of the 160 
stomach for three hours at predetermined time-points, i.e. 5, 15, 25, 40, 50, 60, 70, 80, 90, 100, 110, 161 
120, 130, 140, 150, 160, 170 and 180 minutes after oral drug administration (t0). The volume of gastric 162 
aspirates was kept as small as possible (< 3 mL). Immediately after aspiration, samples were 163 
centrifuged (5 min, 20,817 x g; Microcentrifuge 5424, VWR International, Radnor, PA, USA) in order 164 
to separate liquid from solid material and obtain a homogeneous filtrate. Supernatant was subsequently 165 
filtered through a two-membrane filter system (Chromafil® GF/RC, pore size: 1.0/0.20 µm, diameter: 166 
25 mm; Machery-Nagel, Düren, Germany). After discarding the first ten droplets for reasons of 167 
adsorption, filtrate was collected in a test tube and stored on ice. Subjects were asked to remain seated 168 
in a hospital bed (i.e. semi-supine position) and to not put any external pressure on their stomach (e.g. 169 
laptop) in order not to influence pressure measurements. After three hours of aspiration, the position of 170 
the catheters was checked again via fluoroscopy to ensure aspiration catheters had not markedly 171 
shifted position during the course of the experiment. At the end of the experiment, samples were 172 
frozen at -26°C pending analysis. 173 
 174 
2.3. Sample analysis 175 
In order to determine paromomycin concentrations in gastric aspirates, the compound was linked to a 176 
fluorophore (i.e. Fmoc-Cl) prior to analysis via a method adapted from Kumar et al. [33]. For this 177 
purpose, a mixture of 430 µL boric acid solution (24.7 mg.mL-1 in H2O, pH 8), 20 µL gastric aspirate 178 
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and 500 µL Fmoc-Cl solution (1.03 mg.mL-1 in acetonitrile) was thoroughly vortexed and stored 179 
protected from light to allow for the derivatization reaction to take place. After ten minutes, 50 µL 180 
glycine solution (7.5 mg.mL-1 in boric acid solution) was added to the mixture to stop the reaction. 181 
After a centrifugation step to separate dissolved material from precipitated protein content (5 min, 182 
14000 g, 37°C; Eppendorf™ 5804R Centrifuge, Fischer Scientific, Leicestershire, UK), supernatant 183 
was transferred to a vial for analysis. Concentrations of the derivatization product were determined via 184 
reversed-phase HPLC (RP-HPLC) using a Waters 2695 Separations Module (Waters, Milford, MA, 185 
USA) and a Novapak C18 column under radial compression (pore size 60 Å, particle size 4 mm, 8 mm 186 
i.d. x 100 mm; Waters). The compound was isocratically eluted from the column at a flow rate of 1 187 
mL.min-1 using a mixture of acetonitrile and H2O (87:13, v/v), resulting in a retention time of eight 188 
minutes. After rinsing the column with methanol: acetic acid buffer (25 mM, pH 3.5) (75:25, v/v) and 189 
H2O: acetic acid buffer (25 mM, pH 3.5) (75:25, v/v), the column was reconditioned with mobile 190 
phase. Eluent was detected using fluorescence detection at 260 nm (excitation) / 315 nm (emission) 191 
(Waters 2475 Multiwavelength Fluorescence Detector; Waters, Milford, MA, USA). The method was 192 
fully validated in relevant media within a linear range from 1300 to 10 µM, with all criteria meeting 193 
the FDA requirements for bio-analytical method validation. 194 
 195 
2.4. Data interpretation 196 
To assess the similarity between regional drug concentration-time profiles, a similarity factor (fsim(t)) 197 
was calculated at each aspiration time-point t based on drug concentrations measured:  198 
𝑓𝑠𝑖𝑚(𝑡) (%) = [1 −  
|[drug]antrum (t) − [drug]corpus (t)|
[drug]highest (t)
] × 100 199 
Subsequently, the average similarity factor (fsim) was calculated as a measure of intragastric drug 200 
homogeneity, taking only into account similarity factors based on relevant drug concentrations (i.e. 201 
[drug] ≥ 5% of Cmax for minimally one sampling region) to avoid skewing of results due to very low 202 
drug concentrations at later time-points: 203 
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𝑓𝑠𝑖𝑚(%) =
∑ 𝑓𝑠𝑖𝑚(𝑡)
𝑛
𝑡=1
𝑛
 =  
𝑓1 + 𝑓2 + ⋯ + 𝑓𝑛
𝑛
 204 
n = number of time-points per profile for which fsim(t) was calculated. 205 
A non-parametric Wilcoxon test was performed to evaluate the statistical significance of the obtained 206 
data; differences between test conditions were considered statistically significant at p > 0.05. 207 
 208 
3. RESULTS AND DISCUSSION 209 
3.1. Preliminary findings on intragastric drug distribution 210 
In a pilot study, regional drug concentrations were measured as a function of time in the stomach of 211 
healthy volunteers after oral administration of one tablet Gabbroral® (250 mg paromomycin) with 212 
water (cfr. 2.2.3. Preliminary clinical trial). Conflicting results regarding homogeneity of drug 213 
distribution in the stomach were obtained. For some volunteers, drug concentration-time profiles in 214 
corpus and antrum of the stomach compared reasonably well, whereas for others, regional drug 215 
concentrations measured were more inhomogeneous. Examples illustrating both scenarios are depicted 216 
in Figure 1. A possible explanation for the observed variability in drug distribution throughout the 217 
stomach could hypothetically be found in between-subject differences in gastric motor activity at the 218 
time of dosing. As fasted state gastric motility displays time-dependent fluctuations, it seems likely 219 
that also hydrodynamics in the stomach are prone to marked changes as a function of time. For 220 
example, mixing of gastric contents could be hypothesized to be more efficient during a period of 221 
gastric motor activity compared to a period without gastric contractions. As a result, drug distribution 222 
in the stomach may be affected by the MMC phase during which the drug is administered. According 223 
to this hypothesis, little or no mixing of gastric contents during MMC phase I administration would 224 
result in inhomogeneous distribution of a drug in the stomach, whereas dosing during MMC phase 225 
II/III would lead to more homogeneous drug distribution resulting from the adequate mixing of gastric 226 
contents. Since the pilot study did not provide any information regarding dosing relative to gastric 227 
motor activity, a second study was conducted to investigate this hypothesis. 228 
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 229 
3.2. Influence of gastric motor function on intragastric drug distribution 230 
3.2.1. High resolution manometry to monitor gastrointestinal motility 231 
A multitude of methods can be used to investigate gastrointestinal motility in healthy subjects and 232 
patients [9, 13, 20, 21, 34-37]. For several reasons, it was opted to use the high-resolution manometry 233 
technique in this study. From a practical point of view, the ease of use for the test operator was an 234 
important selection criterion. As a combination with the labour-intensive intraluminal sampling 235 
technique was strived for, the technique of choice should not add an additional burden on the test 236 
operator. Once correctly positioned, the high-resolution manometry catheter is connected to a 237 
computer console after which no additional interventions are required by the operator for the entire 238 
duration of the experiment. This allows the operator to perform additional actions such as blood 239 
sampling and aspiration of gastrointestinal fluids. This feature provides a clear advantage over other 240 
techniques sometimes used to investigate gastrointestinal motility (e.g. MRI, ultrasonography) which 241 
often require continuous hands-on presence of the test operator [36-38]. With regard to the tolerability 242 
of the manometry technique for study participants, intubation via the nose and positioning of the 243 
catheter may provide some temporary discomfort. However, the catheter is generally well-tolerated 244 
once correctly positioned. Importantly, alterations in gastrointestinal physiology (e.g. gastric 245 
emptying, gastric secretions) as a result of the intraluminal presence of a catheter have been reported 246 
to be negligible [39, 40]. 247 
Another important feature of the high-resolution manometry technique is the comprehensibility of the 248 
data output. Whereas several other techniques (e.g. ultrasonography, electrogastrography) require an 249 
expert in the field to interpret experimental data, the manometry technique produces a comprehensible 250 
output in the form of a high-resolution pressure map (Fig. 2) [36, 41]. This pressure map is colour-251 
coded, with colours ranging from blue (no pressure) to pink (pressure > 150 mmHg). Based on the 252 
generated data, valuable information regarding regional gastrointestinal motor activity can be collected 253 
as a function of time. Distinct anatomical regions can easily be identified based on (i) basic knowledge 254 
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of gastrointestinal anatomy and (ii) well-described regional characteristics of gastrointestinal motility 255 
in literature. For example, the transition from oesophagus to stomach is easily distinguished by 256 
relatively high pressure events at the frequency of the subject’s swallowing (Fig 2, section A), which 257 
can be attributed to the sphincter activity at the gastro-oesophageal junction. Secondly, as gastric 258 
contraction waves have been described to intensify towards the pylorus, corpus and antrum regions of 259 
the stomach can be differentiated based on the amplitude of registered contractions [9]. Furthermore, 260 
peristaltic contraction waves originate from midcorpus and subsequently propagate towards the 261 
antrum and pylorus, thus resulting in a small but distinguishable time-delay in onset of antral 262 
contractions compared to the corpus, providing a second identifier for both regions (Fig. 2, sections B 263 
and C). Substantial differences in both contraction frequency and amplitude between antrum and 264 
duodenum again allow reliable identification of both anatomical regions (Fig. 2, sections C and D) 265 
[11, 12].  266 
Although both wireless motility capsules (e.g. IntelliCap®, SmartPill®) and the high-resolution 267 
manometry catheter record gastrointestinal pressures, the information gathered using these techniques 268 
markedly differs. Wireless motility capsules register regional gastrointestinal pressures as a function 269 
of time, however the region in which measurements are recorded varies as the capsule migrates along 270 
the gastrointestinal tract, rendering this technique useful to investigate pressures to which a solid 271 
dosage form is exposed during its transit [20-22]. On the other hand, high-resolution manometry 272 
provides simultaneous data on both gastric and proximal duodenal pressures as a function of time. 273 
Moreover, pressures are recorded from the same regions for the entire duration of the measurements. 274 
Although not pursued in the present study (cfr. 2.2.4. Clinical trial investigating drug distribution), 275 
quantifying the amplitude of gastrointestinal contractions in vivo may be useful for the further 276 
optimization of in vitro predictive tools to be used during drug development.  277 
In the context of investigating gastrointestinal drug disposition, using the high-resolution manometry 278 
technique thus provides the opportunity to accurately determine gastric contractility at the time of oral 279 
dosing. In doing so, the influence of gastric motor function on drug distribution in the stomach could 280 
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be investigated in this study by orally administering a drug both in the presence and absence of gastric 281 
contractions.  282 
 283 
3.2.2.  (In)homogeneity of intragastric drug distribution 284 
Similar as for the pilot study, homogeneity of intragastric drug distribution was assessed by collecting 285 
aspirates from different regions of the stomach as a function of time after oral intake of one tablet 286 
Gabbroral® (250 mg paromomycin) with water. In addition, gastrointestinal motility measurements 287 
were performed in parallel to facilitate drug administration during a specific MMC phase (cfr. 2.2.4. 288 
Clinical trial investigating drug distribution). Paromomycin, a BCS Class III drug, was chosen as a 289 
model compound to investigate drug distribution in the stomach of fasted healthy volunteers. Due to 290 
its high solubility within a wide pH range and its very low intestinal permeability, this compound has 291 
previously been used as a marker for gastrointestinal transfer of drug solutions [31]. In this study, a 292 
lack of solubility-restrictions throughout the gastrointestinal tract ensures the absence of interfering 293 
intraluminal processes (e.g. drug precipitation), facilitating the correct interpretation of regional drug 294 
concentrations measured in the stomach as a function of time. Furthermore, by comparing catheter 295 
position prior to and after the experiment, sampling of gastric contents in distinctly different regions of 296 
the stomach throughout the experiment was ensured (Fig. 3). 297 
Figure 4 depicts the individual regional drug concentration-time profiles in all volunteers for both 298 
conditions tested in the clinical study. Based on these profiles, the similarity between concentrations 299 
measured in the antrum and corpus region of the stomach was calculated (cfr. 2.4. Data 300 
interpretation). Regardless of gastric motor function at the time of dosing, similarity of regional drug 301 
concentration-time profiles was highly variable among volunteers (Fig. 5). Overall, fsim values 302 
calculated ranged from 14.29 to 79.84%. A low fsim value indicates inhomogeneous drug distribution 303 
in the stomach, whereas a high fsim value suggests adequate mixing of gastric contents with an orally 304 
administered drug. The wide range of fsim values observed in this study challenges the traditional 305 
thinking with regard to drug distribution. Rather than being rapidly distributed throughout the stomach 306 
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after dosage form disintegration, homogeneous intragastric drug distribution may in some cases be 307 
markedly hampered. With regard to the underlying mechanism determining intragastric drug 308 
distribution, a link between (in)homogeneity and fasted state gastric motility was observed in this 309 
study. With the model compound administered during a period of contractile quiescence (i.e. MMC 310 
phase I), median fsim calculated from individual fsim values for all healthy volunteers, amounted to 311 
28.25% (Fig. 5). This finding supports the hypothesis regarding impaired mixing of gastric contents in 312 
the absence of gastric contractions. However, three healthy volunteers (V03, V06 and V08, Fig. 4 and 313 
5) displayed remarkably better similarity between regional drug concentrations compared to the 314 
median fsim for this group (63.8 - 75.24% vs. 28.25%, respectively); this indicates that, despite the 315 
absence of gastric contractions, drug distribution in the stomach may still be adequate in some cases. 316 
Drug administration in the presence of gastric contractions resulted in a median fsim of 57.64% 317 
between regional concentration-time profiles. Comparing both test conditions, a trend towards more 318 
homogeneous drug distribution in the presence of gastric contractions can be deduced, as illustrated by 319 
a two-fold increase in median fsim during phase II drug administration compared to phase I 320 
administration (57.64 vs. 28.25%, respectively; p > 0.05, NS). Additionally, it would have been 321 
interesting to investigate the inter-individual variability in contraction amplitude and how this may 322 
relate to differences observed in similarity of regional profiles.  323 
Notably, drug administration in the presence of gastric motor activity does not automatically guarantee 324 
homogeneous intragastric drug distribution. The median value is in this case influenced by fsim values 325 
which are lower than anticipated based on our hypothesis. These counterintuitive findings again point 326 
towards other factors influencing distribution of an orally administered drug in the stomach.  327 
In the context of additional determinants of intragastric drug distribution, factors such as medium 328 
viscosity and site-specific dosage form disintegration may be considered. Several authors have 329 
performed in vitro experiments investigating the impact of changes in medium viscosity on dosage 330 
form disintegration and drug dissolution in an attempt to elucidate negative food effects for BCS Class 331 
I and III drugs [7, 42-44]. In all cases, disintegration and dissolution processes were found to be 332 
markedly delayed after addition of viscosity-enhancing agents to traditionally used buffer media. 333 
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Despite the fact that these experiments aimed to mimic changes in rheological properties of gastric 334 
fluids after food intake, the results may to some extent also apply to gastric fluids under fasted state 335 
conditions. Although viscosity of gastric contents is generally assumed to be significantly higher under 336 
fed state conditions, Pedersen et al. reported marked viscosity in several gastric aspirates from fasted 337 
healthy volunteers, in line with our in-house experience [45, 46]. As processes such as dosage form 338 
disintegration and dissolution are significantly affected by the viscosity of the medium, an impact of 339 
viscosity on drug distribution due to impaired diffusivity and increased resistance to fluid flow may be 340 
possible. This may in some cases result in localized drug release, even in the presence of gastric 341 
contractions. Stamatopoulos et al. further explored this hypothesis by visualizing fluid flow patterns 342 
and investigating their relation to mixing and drug distribution in an in vitro setup (USP 2 mini 343 
vessel). When medium viscosity was artificially increased, hydrodynamics markedly changed 344 
resulting in a worsening of fluid mixing compared to the reference medium. To investigate the 345 
subsequent impact on drug distribution, the authors performed dissolution experiments with 346 
theophylline tablets determining drug concentrations in samples taken from multiple sampling sites as 347 
a function of time. A marked difference in drug concentrations measured at different sites was 348 
observed as the viscosity of the medium increased [6]. Although the hydrodynamics in these 349 
experiments do not resemble the in vivo situation, results indicate that viscosity of gastric fluids may 350 
indeed contribute to inhomogeneous mixing of gastric contents. Using a video-endoscopic technique, 351 
Graham et al. attempted to visualize gastric dispersion of KCl crystals formulated as multiparticulate 352 
dosage forms (i.e. a capsule or a tablet) in healthy volunteers. Their findings suggest that these crystals 353 
may in some cases be regionally present in very high concentrations due to drug ‘entrapment’ in 354 
gastric mucus [47, 48].  355 
A second factor potentially affecting intragastric drug distribution is the location of the administered 356 
dosage form within the stomach. For instance, Weitschies et al. reported marked variability in 357 
intragastric tablet location between subjects [49]. As contractility patterns and amplitude of 358 
contractions display site-specific characteristics (e.g. proximal corpus vs. antrum), forces acting on a 359 
dosage form may vary substantially depending on its intragastric location [8, 9, 50]. Therefore, 360 
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disintegration of a dosage form located in the proximal stomach may be less affected by intense antral 361 
contractions compared to dosage forms residing in the distal stomach [47, 49]. As a result, drug 362 
dispersion and distribution throughout the stomach may be hampered. Due to the fact that the study 363 
design did not allow to determine the location of the administered tablet within the stomach, a possible 364 
influence of between-subject differences in intragastric location of the dosage form could not be ruled 365 
out. Furthermore, although the position of the subjects during the experiment was standardized (i.e. 366 
semi-supine) in an attempt to cancel out differences in stomach shape and dosage form location due to 367 
posture (e.g. upright vs. supine), a multitude of variations in stomach anatomy have been previously 368 
reported, potentially influencing the results observed in this study [51]. 369 
 370 
4. CONCLUSIONS AND FUTURE PERSPECTIVES 371 
In this proof-of-concept study, the feasibility of combining intraluminal sampling of gastrointestinal 372 
aspirates after oral drug administration with simultaneous recordings of gastrointestinal pressures via 373 
high-resolution manometry was explored. The high-resolution manometry technique is easy in use and 374 
well-tolerated by the study participants. Furthermore, the data output from this technique is 375 
comprehensible and provides valuable information regarding gastrointestinal motility in a time-376 
dependent manner. Therefore, the combination with the intraluminal sampling of gastric fluids was 377 
found to be very useful to explore possible links between gastrointestinal motility and drug 378 
disposition.  379 
In a first application, the influence of fasted state gastric motor function on intragastric drug 380 
distribution in healthy volunteers was investigated. A clear trend towards better mixing of an orally 381 
administered drug with gastric contents was observed in the presence of gastric contractions, resulting 382 
in a more homogeneous distribution of the drug throughout the stomach. Although a link between 383 
gastric motor function and drug distribution was established, several other factors may contribute to 384 
the intragastric dispersion and distribution of a drug (e.g. tablet location, medium viscosity). The 385 
results obtained in this study challenge the concept of the stomach as a simple dissolution vessel, as 386 
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similarity in regional drug concentrations displayed marked between-subject variability and was 387 
observed to be far from homogeneous in all test conditions. In the future, quantification of 388 
intraluminal pressures in a large set of both healthy volunteers and patients may be of interest as these 389 
data could be used as a reference for the further optimization of in vitro tools. Furthermore, more 390 
research is needed to investigate gastrointestinal motility as a source of variability in intraluminal 391 
processes such as dosage form disintegration and, eventually, in systemic drug exposure. 392 
 393 
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Figure captions 
 
Figure 1. Regional drug concentration-time profiles obtained from two volunteers in the pilot study 
after oral administration of one tablet Gabbroral® (250 mg paromomycin) with 240 mL tap water. ■ 
Regional drug concentrations measured in corpus region of the stomach as a function of time. ● 
Regional drug concentrations measured in antrum region of the stomach as a function of time. 
 
Figure 2. Colour-coded high-resolution pressure map generated using high-resolution manometry, 
depicting typical late phase II/phase III gastrointestinal contractions. Colours range from blue to pink, 
indicating contraction amplitude. Distinct regions can be identified: A. Gastro-oesophageal junction, 
B. Corpus, C. Antrum, D. Duodenum. 
 
Figure 3. Catheter position in a healthy volunteer at the beginning (a) and the end of the study (b), 
verified using fluoroscopic imaging. Aspiration catheters are positioned in corpus (A) and antrum (B) 
region of the stomach, respectively. The high-resolution manometry catheter can easily be 
distinguished by the dotted line, in which each dot represents an individual pressure channel.  
 
Figure 4. Individual regional drug concentration-time profiles from all volunteers (n = 8) for both test 
conditions. ■ Drug concentrations measured in the corpus region of the stomach as a function of time. 
● Drug concentrations measured in the antrum region of the stomach as a function of time. 
 
Figure 5. Similarity of regional drug concentration-time profiles, expressed as fsim, as a function of 
MMC phase during which a drug is administered. Cross-over nature of the study is illustrated by the 
use of a unique symbol for each volunteer. Horizontal lines depict median fsim values in both test 
conditions. 
 
 
